Research Topics
| James A DykensSummaryAffiliation: Pfizer Global Research and Development Country: USA Publications
| Collaborators
|
Detail Information
Publications
The significance of mitochondrial toxicity testing in drug developmentJames A Dykens
Drug Safety Research and Development, Pfizer Inc, 10646 Science Center Drive, San Diego, CA 92121, United States
Drug Discov Today 12:777-85. 2007....- Strategies to reduce late-stage drug attrition due to mitochondrial toxicityJames A Dykens
Pfizer DSRD, 10646 Science Center Drive, San Diego, CA 92121, USA
Expert Rev Mol Diagn 7:161-75. 2007..This dichotomy encourages optimism that efficacy can be disassociated from mitochondrial toxicity, resulting in safer drugs in the future... - Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitroJames A Dykens
Drug Safety Research and Development, Pfizer, Inc, Ramsgate Rd Sandwich, CT13 9NJ, UK
Toxicol Appl Pharmacol 233:203-10. 2008..Indeed, the desired clinical outcome, viz., decreased blood glucose, could be due to increased glucose uptake and glycolytic flux in response to drug-induced mitochondrial dysfunction... - A current practice for predicting ocular toxicity of systemically delivered drugsChris J Somps
Drug Safety Research and Development, Pfizer Global R and D, Groton, CT 06340, USA
Cutan Ocul Toxicol 28:1-18. 2009..This review summarizes a current practice for minimizing the potential for systemically administered, new medicines to cause adverse effects in the eye... - Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicantsLisa D Marroquin
Pfizer DSRD, San Diego, CA 92121, USA
Toxicol Sci 97:539-47. 2007..Some drugs were equally toxic to both glucose- and galactose-grown cells, suggesting that mitochondrial impairment is likely secondary to other cytotoxic mechanisms... - Development of 17alpha-estradiol as a neuroprotective therapeutic agent: rationale and results from a phase I clinical studyJames A Dykens
MIGENIX Corporation, 12780 High Bluff Dr, San Diego, CA 92130, USA
Ann N Y Acad Sci 1052:116-35. 2005..Positive safety and pharmacokinetic data from a successful phase I clinical study with oral 17alpha-E2 (sodium sulfate conjugate) are presented here, and several options for its future clinical assessment are discussed... - Novel mechanisms for estrogen-induced neuroprotectionMeharvan Singh
Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA
Exp Biol Med (Maywood) 231:514-21. 2006..On the basis of this evidence, we discuss the clinical applicability of estrogens in treating various age-related disorders, including Alzheimer disease and stroke, and identify the caveats that must be considered... - Mitochondrial mechanisms of estrogen neuroprotectionJames W Simpkins
Department of Pharmacology and Neuroscience, Institute for Aging and Alzheimer s Disease Research, University of North Texas Health Science Center, 3500 Camp Bowie Boul, Fort Worth, TX 76102, USA
Brain Res Rev 57:421-30. 2008.... - Mitochondria play a central role in estrogen-induced neuroprotectionJames W Simpkins
Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76102, USA
Curr Drug Targets CNS Neurol Disord 4:69-83. 2005.... - Oxidative damage to human lens epithelial cells in culture: estrogen protection of mitochondrial potential, ATP, and cell viabilityXiaofei Wang
Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas 76107, USA
Invest Ophthalmol Vis Sci 44:2067-75. 2003....